Clinical Trial Update: Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol [Phase 3]

View source ↗

Summary

This Phase 3 trial by Axsome Therapeutics evaluates solriamfetol for major depressive disorder, targeting TAAR-1, dopamine, and norepinephrine pathways; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Solriamfetol (solriamfetol)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED